Prevention of Adolescent Risky Behaviors: Neural Markers of Intervention Effects
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03370393 |
Recruitment Status :
Recruiting
First Posted : December 12, 2017
Last Update Posted : November 5, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Risk-Taking Adolescent Behavior | Behavioral: Pathways for African-Americans' Success (PAAS) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 128 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | The families will be randomized to Pathways for African Americans' Success (PAAS) intervention program or a wait-list condition (1:1 ratio) for 6 weeks. The wait-list group has the option to participate in the PAAS program at the end of the study. |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Prevention of Adolescent Risky Behaviors: Neural Markers of Intervention Effects |
Actual Study Start Date : | December 11, 2017 |
Estimated Primary Completion Date : | December 2022 |
Estimated Study Completion Date : | December 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Pathways for African-Americans' Success
Subjects will complete a 6-week Pathways for African-Americans' Success (PAAS) intervention. This is a weekly, 1.5 hour/session, family intervention for 6 weeks.
|
Behavioral: Pathways for African-Americans' Success (PAAS)
PAAS is a 6-week, technology-delivered, family-based youth risk intervention program. PAAS includes 6 sessions for parents and youth, and joint sessions in which they both engage on the same computer to integrate and practice the skills they have just learned in their separate sessions. Each session includes a review, a virtual discussion, and observing and interacting with four parent and four youth Avatars that reflect phenotypes of AAs, with voice-overs by AA parents and youth. Videos portraying family interactions and intrapersonal processes are integrated into each session to convey key points of the intervention along with interactive activities to promote skill-building and to reinforce learning. PAAS also includes a technology tutorial and an introductory session. |
No Intervention: Wait-list
Subjects will be on waiting list for active intervention and will receive the PAAS intervention at the end of the study (same as active intervention).
|
- Changes in fronto-striatal functional connectivity [ Time Frame: 6 weeks ]Changes in fronto-striatal functional connectivity at rest and while performing a probabilistic reward task during an MRI scan from baseline to post-intervention
- Changes in emotional regulation [ Time Frame: 3 months post-intervention ]Emotional regulation will be assessed through parent and youth self-reported questionnaires, and summary scores will be derived from these questionnaires administered at baseline (before intervention) and 3 months post-intervention
- Changes in cognitive regulation [ Time Frame: 3 months post-intervention ]Cognitive regulation will be assessed through parent and youth self-reported questionnaires, and summary scores will be derived from these questionnaires administered at baseline (before intervention) and 3 months post-intervention

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 11 Years to 14 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Subject is of African-American racial status (self-reported)
- Subject can speak and read English
- Subject and parent/legal guardian agree to participate in the 6-week PAAS program
- Subject and parent/legal guardian agree to complete all assessments
- Subject must meet MRI safety eligibility
Exclusion Criteria:
- Subject has a major medical problem (e.g. neurological disorders)
- Subject is on medication(s) that affects the central nervous system
- Subject has behavioral/emotional problems at a clinical level (parent and/or youth report)
- Subject is pregnant or suspected of being pregnant (based on pregnancy test)
- Subject is color-blind
- Subject has claustrophobia
- Subject has metallic implants
- Subject drinks alcohol in the week prior to entry into the study (based on urine drug screen)
- Subject uses drugs in the week prior to entry into the study (based on urine drug screen)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03370393
Contact: Anna Ter-Grigoryan, BS | (949) 824-3770 | tergriga@uci.edu | |
Contact: Adriana Pedroza, BA | (949) 824-7056 | apedroz5@uci.edu |
United States, California | |
University of California, Irvine | Recruiting |
Irvine, California, United States, 92617 | |
Contact: Anna Ter-Grigoryan, BS 949-824-3770 tergriga@uci.edu | |
Contact: Adriana Pedroza, BA (949) 824-7056 apedroz5@uci.edu | |
Principal Investigator: Uma Rao, MD |
Principal Investigator: | Uma Rao, MD | University of California, Irvine |
Documents provided by Uma Rao, University of California, Irvine:
Responsible Party: | Uma Rao, Professor and Vice Chair, University of California, Irvine |
ClinicalTrials.gov Identifier: | NCT03370393 |
Other Study ID Numbers: |
2017-3439 |
First Posted: | December 12, 2017 Key Record Dates |
Last Update Posted: | November 5, 2020 |
Last Verified: | November 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Reward-drive Cogntiive-control |